We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
- Authors
Serisier, David J; Bilton, Diana; De Soyza, Anthony; Thompson, Philip J; Kolbe, John; Greville, Hugh W; Cipolla, David; Bruinenberg, Paul; Gonda, Igor; ORBIT-2 investigators
- Abstract
The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis. Dual release ciprofloxacin for inhalation (DRCFI) contains liposomal ciprofloxacin, formulated to optimise airway antibiotic delivery.
- Publication
Thorax, 2013, Vol 68, Issue 9, p812
- ISSN
1468-3296
- Publication type
Journal Article
- DOI
10.1136/thoraxjnl-2013-203207